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ABSTRACT
Objective: The purpose of this study was to document real-world treat-
ment patterns, medication adherence, and the impact of adherence on
disease-speciﬁc and all-cause health-care costs among chronic hepatitis C
virus (HCV) patients in a US managed care population.
Methods: Commercial insurance claims data between January 1, 2002 and
December 31, 2006 from the Ingenix Impact (formerly Integrated Health
Care Information Services) database were retrospectively analyzed.
Chronic HCV patients with one or more prescriptions for an HCV-speciﬁc
treatment within 6 months before or at any time after their ﬁrst observed
diagnosis of chronic HCV were selected. Prescribing patterns, treatment
cost, and duration of treatmentwere assessed over the entire therapy period.
Medication adherence rates and the relationship between adherence and
health-care costs were assessed over the 24-week period after treatment
initiation. The results were stratiﬁed by key clinical characteristics such as
genotype, sustained virologic attainment, and disease severity.
Results: Results showed that peginterferon and ribavirin combination
regimens were the most common treatments for chronic HCV. The
patients underwent treatment for approximately 30–32 weeks on average,
and treatment costs were over $20,000 per patient. Adherence to medi-
cation was suboptimal, especially among patients with severe disease.
Adherent patients had higher pharmacy costs but signiﬁcantly lower total
costs when pharmacy was excluded.
Conclusions: New and improved treatments that promote better adher-
ence and impose a lower cost burden on patients and payers are needed.
Keywords: adherence, managed care, Peginterferon, ribavirin, treatment
cost.
Introduction
Hepatitis C virus (HCV) has been recognized over the past two
decades as an emerging public health problem. Over 180 million
people are infected with HCV worldwide [1]. Estimates by the
Centers for Disease Control and Prevention (CDC) suggest that it
is one of the most common blood-borne infections in the United
States and affects approximately 3.2 million people [2], with
17,000 new acute cases detected each year [3]. At least three
quarters of cases of HCV develop into long-term or chronic
infections [4]. Over time, approximately 20% of chronically
infected patients develop cirrhosis of the liver [5] and other
complications such as hepatocellular carcinoma, leading to an
increased need for liver transplants.
The CDC estimates that nearly 8000–10,000 deaths are due
to chronic liver disease each year [6]. As the duration of infection
increases among surviving HCV patients, the burden of disease is
also likely to rise. It is estimated that the proportion of patients
with cirrhosis will increase from 16% to 20% by 2020 and that
hepatocellular carcinoma will increase by 81% and liver-related
deaths will increase by 180% [7]. Because the age group most
frequently diagnosed with HCV, people aged 30–49 years, is
likely to be employed and enrolled in an employer-based insur-
ance plan, the burden of HCV in the United States falls largely on
managed care payers [8].
Early diagnosis and treatment of chronic HCV can do the
following: reduce hepatic inﬂammation; prevent progression to
ﬁbrosis, cirrhosis, and hepatocellular carcinoma by eliminating
the virus in chronically infected patients; and control the spread
of disease [9]. Current treatments for chronic HCV include com-
bination peginterferon (alfa-2a or alfa-2b) regimens with ribavi-
rin, peginterferon monotherapies, combination interferon
(alfa-2a or alfa-2b) regimens with ribavirin, interferon mono-
therapies, interferon alfacon-1 (consensus interferon) regimens
with ribavirin, and consensus interferon monotherapy. Although
there has been signiﬁcant progress in the treatment of chronic
HCV over the past two decades, there continues to be a large
unmet need because of low rates of sustained virologic response
(SVR) and a signiﬁcant proportion of relapses and nonresponses.
Current therapies also are associated with a high incidence of
adverse events, leading to low adherence, therapy discontinua-
tion, and/or dose reduction.
Despite the potential long-term burden of chronic HCV on
managed care systems and the persistent unmet need in this
population in spite of existing treatments, there have been no
studies that provide a comprehensive understanding of real-
world prescribing patterns of and adherence with key HCV
therapies. This article seeks to address this gap by analyzing
retrospective commercial claims data to examine treatment pat-
terns and medication adherence among US managed care enroll-
ees with chronic HCV. We also examine the impact of medication
nonadherence on HCV-speciﬁc and all-cause health care costs.
An understanding of current treatment patterns in this popula-
tion may help inform payers and practitioners about the thera-
peutic landscape as novel antiviral and interferon therapies for
chronic HCV become available.
Methods
Data Source
Data were taken from the Ingenix Impact (formerly known as the
Integrated Health Care Information Services) database contain-
ing medical (inpatient, outpatient, physician, ancillary) and phar-
macy claims from a national sample of 40 managed care health
plans covering approximately 50 million lives. The database has
a representative distribution of age and sex compared with
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national enrollment in managed care plans. Geographic repre-
sentation, however, is biased toward the East Coast. Claims
records in the Ingenix Impact database contain information on
patient characteristics that include the following: demographics
eligibility for beneﬁts; diagnoses (including primary and up to
two nonprimary diagnosis codes); detailed information about
hospitalizations, diagnostic testing, and therapeutic procedures;
inpatient and outpatient physician services; prescription drug
use; and cost data in the form of managed care reimbursed
amounts for each service. Results for selected laboratory tests are
also available for a subset of patients. Unique patient identiﬁca-
tion numbers in the Impact database allow patients to be tracked
longitudinally.
Study Population
Patients with a diagnosis of chronic HCV (International Classi-
ﬁcation of Diseases, 9th Edition, Clinical Modiﬁcation [ICD-
9-CM] codes 070.44, 070.54, 070.70, and 070.71) between
January 1, 2002 and December 31, 2006, the ﬁve most recent
years of Ingenix Impact data available for this analysis, were
selected for initial study inclusion. The patients also were
required to have no evidence of hepatitis B virus, identiﬁed by
ICD-9-CM codes 070.2x and 070.3x (including all ﬁfth digit
modiﬁers) at any point during their claims history. The patients
with acute HCV (ICD-9-CM codes 070.41 and 070.51) were
excluded from the study sample if they did not also have at least
one diagnosis of chronic HCV.
The patients were required to receive at least one HCV treat-
ment at any time 6 months before or any time after the ﬁrst
observed HCV diagnosis. The patients were allowed to receive
treatment before their ﬁrst observed HCV diagnosis because we
cannot identify the true date of HCV onset in our study data.
Given the chronic nature of HCV, it is likely that many patients
were diagnosed several years before the start of the study database
or before enrollment in a health plan captured by the database.
Our study sample, therefore, represents patients identiﬁed on the
basis of a new episode of treatment who have current diagnostic
evidence of HCV, rather than truly incident (i.e., new) HCV cases.
HCV treatments included combination peginterferon alfa-2a
plus ribavirin (PEG2A + R), peginterferon alfa-2b plus ribavirin
(PEG2B + R), peginterferon alfa-2a monotherapy (PEG2A),
peginterferon alfa-2b monotherapy (PEG2B), combination inter-
feron alfa-2a plus ribavirin (IFN2A + R), interferon alfa-2b plus
ribavirin (IFN2B + R), interferon alfa-2a monotherapy (IFN2A),
interferon alfa-2b monotherapy (IFN2B), consensus interferon
regimen with ribavirin (IFN + R), and consensus interferon
monotherapy (CIFN).
An index date was deﬁned as the date of the ﬁrst observed
prescription for an HCV treatment. To ensure that each patient’s
index date was a reasonable marker for new treatment initiation,
the patients included in this study sample were required to have
at least 6 months of continuous health plan enrollment before
their index date, with no evidence of prescriptions for HCV
treatment during that time frame. To ensure that any observed
lack of health-care events after treatment initiation was due to a
true lack of medical activity and not cessation of insurance, the
patients included in the study sample were required to have at
least 12 months of medical and pharmacy beneﬁts eligibility after
their index date.
Baseline Patient Characteristics
Baseline characteristics that were measured at the index date
included age, gender, geographic region, insurance payer type
(e.g., commercial, Medicare, Medicaid), and health plan type
(e.g., health maintenance organization, preferred provider orga-
nization). To assess overall comorbidity burden before the index
date, we also calculated a Charlson Comorbidity Index (CCI)
score for each patient. The CCI includes 17 categories of comor-
bidities, as deﬁned by ICD-9 diagnosis codes, with associated
weights corresponding to the severity of the comorbid condition
of interest [10]. A higher CCI score represents a higher overall
comorbidity burden. A single CCI score was calculated for each
patient based on the presence of the corresponding diagnosis
during the 6-month period before the index date. In addition to
baseline demographics and comorbidity burden, we estimated
the distribution of genotype and disease severity in the subset of
each patient sample for which the appropriate laboratory results
were available.
Outcome Measures
We documented patterns of drug prescribing and treatment of all
the key HCV therapies among patients with chronic HCV. The
distribution of patients initiating each of the treatment regimens,
the average number of prescriptions, the average duration of
therapy, and the average cost of therapy were estimated and
reported. For combination therapies, the number, duration, and
cost of prescriptions were computed separately for the two drugs.
The average number of prescriptions and average costs were
computed across all prescription claims for that drug starting
with the index (ﬁrst observed) prescription. Duration of therapy
was computed as the total number of days between treatment
initiation and treatment completion or discontinuation. Therapy
discontinuation was deﬁned as an observed reﬁll gap of at least
90 days between the end of one prescription and the start of the
next prescription.
Adherence to therapy was measured by the patients’ cumula-
tive exposure to chronic HCV treatments over a 24-week period
after treatment initiation. Because of the unavailability of geno-
type information for all the patients, we were unable to measure
adherence over the entire treatment period because the intended
treatment duration for the patients was not known in the absence
of reliable genotype data. All of the patients, regardless of geno-
type, were expected to be treated for a minimum of 24 weeks. For
the patients whowere treated beyond 24weeks, we alsomeasured
adherence over a 48-week period under the assumption that these
patients, if treated more than 24 weeks, were genotype 1 or 4 and
were intended to complete a full 48-week regimen.
We used the medication possession ratio (MPR) to capture
treatment exposure. A recent systematic literature review [11]
found MPR to be the most widely adopted measure (57% of all
studies) in published claims-based analyses of medication adher-
ence. MPR generally is deﬁned as the proportion of days within
an observation period covered by the total days’ supply for a
particular study drug within the observation period: MPR = sum
of days’ supply in observation period/days in observation period.
As noted in Andrade et al. [11], the observation period used
in the MPR calculation is typically either a ﬁxed number of days
within a follow-up period (i.e., 24 weeks after treatment initia-
tion) or the number of days between the ﬁrst dispense date and
end of the days’ supply of the last reﬁll for the study therapy of
interest. Use of the latter denominator in the MPR deﬁnition,
however, does not capture the negative adherence effect of early
therapy discontinuation. To account for discontinuation, we
therefore deﬁned the denominator of the MPR formula as a ﬁxed
value of 158 days (i.e., 24 weeks) so that those patients who
discontinue therapy completely before the end of the follow-up
period will correctly have a lower MPR. For the patients who
were treated beyond 48 weeks, we deﬁned the denominator of
the MPR formula as 336 days (i.e., 48 weeks).
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The patients with an MPR of less than 0.8 (i.e., less than 80%
adherence) were classiﬁed as nonadherent. The 80% threshold
for identifying adherence has been the methodological basis of
numerous adherence studies previously conducted [12–14]. In
addition, the 80-80-80 rule, wherein patients who take 80% of
their peginterferon therapy and 80% of their ribavirin therapy at
least 80% of the time are more likely to achieve SVR, has been
well-documented in the HCV literature [15].
To evaluate the direct economic impact of adherence, HCV-
related and all-cause resource use and costs were calculated over
the 24-week period after treatment initiation and stratiﬁed by
adherent versus nonadherent patients. All cost data were
adjusted to 2007 US dollars and represent reimbursed amounts
paid by health plans to providers. Resource use was grouped
according to the setting in which the service was delivered,
including hospital admissions, skilled nursing facility admissions,
emergency room, physician ofﬁce, home health visits, laboratory
services, prescription drugs, and a residual category capturing all
other outpatient and ancillary services. The subset of all-cause
resource use and costs speciﬁcally related to HCV were identiﬁed
as those claims with a primary or nonprimary (i.e., up to the
third code) ICD-9-CM diagnosis code for chronic HCV. HCV-
related pharmacy utilization was identiﬁed as the subset of pre-
scription drug claims for the HCV therapies described previously.
Analysis Stratiﬁcation
All analyses were stratiﬁed by relevant clinical characteristics,
such as viral genotype, SVR attainment, and proxy indicators for
disease severity, for subsets of patients with valid laboratory
results, and other information required for constructing these
analysis strata. The patients with available genotype results were
stratiﬁed into genotype 1 versus genotype 2/3. For the subset of
patients with available HCV ribonucleic acid (RNA) test results,
SVR attainment status was assessed. SVR attainment is clinically
measured as an undetectable HCV viral RNA test result at least
6 months after completion of treatment [16]. In this study, the
patients were identiﬁed as having attained SVR if an HCV RNA
test performed at any point at least 6 months after therapy
completion or discontinuation showed the viral load to be unde-
tectable. If a patient had multiple, valid HCV RNA tests, the ﬁrst
valid result observed at least 6 months after therapy completion
or discontinuation was used.
Because of lack of liver biopsy data in the claims database, the
aspartate aminotransferase to platelet ratio index (APRI) score
was used as a proxy measure for disease severity. The APRI score
has been used in previous studies as a noninvasive marker of liver
ﬁbrosis and cirrhosis [17]. APRI scores could be computed for
the subset of patients with at least one valid laboratory result for
both an aspartate aminotransferase and a platelet count test
(occurring on the same day) during the 6-month period preceding
the index date. For the patients with multiple, valid test results,
the most recent result (i.e., closest to the index date) was used.
The patients were classiﬁed into mild (APRI  0.5), moderate
(0.5 < APRI  1.5), and severe (APRI > 1.5).
Results
Patient Characteristics
A total of 5086 patients with chronic HCV met all study inclu-
sion criteria. Table 1 presents descriptive statistics on various key
baseline demographic characteristics. Approximately two-thirds
of the patients were male and had an average age of 48 years.
More than 55% of all the patients were in the 45- to 54-year-old
age group. Nearly 64% of all the chronic HCV patients were
located in the Northeast region. Over 97% of all the patients
were enrolled in commercial health insurance plans. Health
maintenance organizations and preferred provider organizations
were the most common plan types among these patients. The
mean baseline CCI score for the sample was 1.77.
Table 2 presents the distribution of genotype, disease severity,
and SVR attainment among the subgroup of patients who had a
Table 1 Key demographic characteristics of the study sample
Chronic HCV
(N = 5086)
N (%)
Gender
Female 1715 (33.72)
Male 3371 (66.28)
Age
Mean; standard deviation 48.34; 7.90
Median 49
Range; minimum, maximum 6, 77
Age category
<18 17 (0.33)
18–24 51 (1.00)
25–34 171 (3.36)
35–44 1076 (21.16)
45–54 2847 (55.98)
55–64 855 (16.81)
65+ 69 (1.36)
Geographic region
Northeast 3076 (60.48)
South 1191 (23.42)
Midwest 442 (8.69)
West 374 (7.35)
Unknown 3 (0.06)
Health plan type
HMO 2021 (39.74)
POS 842 (16.56)
PPO 2081 (40.92)
IND 97 (1.91)
Other 45 (0.88)
Payer type
Commercial 4972 (97.76)
Medicaid 94 (1.85)
Medicare 20 (0.39)
Charlson comorbidity score
Mean; standard deviation 1.77; 2.03
Median 1
Range: minimum, maximum 0, 14
HCV, hepatitis C virus; HMO, health maintenance organization; IND, independent; POS, point
of service; PPO, preferred provider organization.
Table 2 Key clinical characteristics of the study sample
Chronic HCV
(N = 5086)
N (% among
those assessed)
Genotype
Genotype 1 75 (71.43)
Genotype 2/3 30 (28.57)
Not available 4981 (–)
Disease severity (based on APRI scores)
Mild (APRI 0.5) 813 (74.94)
Moderate (0.5 < APRI 1.5) 222 (20.46)
Severe (APRI > 1.5) 50 (4.61)
Not available 4001 (–)
SVR attainment (6 months post-treatment
completion/discontinuation)
Yes 336 (58.43)
No 239 (41.57)
Not available 4511 (–)
APRI, aspartate aminotransferase to platelet ratio index; HCV, hepatitis C virus; SVR,
sustained virologic response.
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valid laboratory test required for the classiﬁcation of that char-
acteristic. Additional tabular data are available upon request
showing the distribution of various patient characteristics
between the relevant categories of each clinical characteristic.
Only 105 chronic HCV patients had a valid genotype, of which
more than two-thirds were genotype 1. The patients were simi-
larly distributed by gender, age, geographic region, and insurance
characteristics regardless of genotype (P > 0.05 for genotype 1
vs. genotype 2/3 in all measures).
Disease severity could be assessed for 1085 patients with
chronic HCV. Nearly 75% of these patients had mild disease,
20% had moderate disease, and 5% had severe disease. The
males comprised a substantially higher proportion of patients
with moderate and severe disease (71% and 74%, respectively)
compared with mild disease (59%) (P = 0.0008). The patients
with mild disease were younger, on average, than the patients
with severe disease (48 vs. 52 years; P < 0.0001), but no statis-
tical difference in age was found when comparing mild with
moderate disease (48 vs. 50 years; P = 0.2348). The proportion
of the patients 44 years of age or younger was substantially
higher in mild disease (27%) compared with moderate and severe
(12% and 12%, respectively; all P < 0.0001).
SVR attainment could be examined for 575 patients with
chronic HCV, of whom 336 (58%) attained SVR when measured
6 months or after treatment completion or discontinuation.
Gender and age distributions did not vary signiﬁcantly (P > 0.05
for all measures) by SVR status, but patients residing in the
Northeast represented a substantially higher proportion of the
patients who did not attain SVR (82%) compared with those
who did attain SVR (62%) (P < 0.0001). The reason for this
difference was not examined, but variations in region-speciﬁc
practice patterns, formulary structures, demographic factors
such as ethnicity and marital status or socioeconomic factors
such as income could contribute to the difference either directly
or through variation in compliance rates. For example, a larger
proportion of patients living in the Northeast might be from
ethnic backgrounds that have historically lower response rates.
This should be evaluated in future studies.
Overall Treatment Prevalence
The number and percentage of the patients that initiated various
HCV treatments are reported in Table 3. In addition, the number
of months between ﬁrst observed diagnosis and treatment initia-
tion also is reported. Over 90% of the chronic HCV patients
initiated treatment with PEG2A + R or PEG2B + R. IFN2A or
IFN2B use (monotherapy or in combination with ribavirin) was
the least common treatment used. Among the chronic HCV
patients who initiated treatment within a 6-month period before
ﬁrst diagnosis, the average time between ﬁrst observed diagnosis
and treatment initiation was 2.2 months. Among those patients
who initiated treatment after ﬁrst observed diagnosis, the average
length of time between diagnosis and treatment initiation was
nearly 7 months. Although the patients initiated treatment up to
47 months after diagnosis, more than 90% initiated treatment
within the ﬁrst 12 months after diagnosis.
Treatment Patterns and Adherence
Table 4 displays the average number of prescriptions, the average
prescription cost, the average duration of therapy, and the rate of
discontinuation for the patients who initiated HCV therapies.
Treatment patterns for IFN2A and IFN2B monotherapies,
IFN2A + R and IFN2B + R combination therapies, and IFN
monotherapy are not reported because of small sample sizes
(n  15).
The patients on PEG2A + R treatment had nearly eight
PEG2A prescriptions on average during their treatment period
and nearly the same number of ribavirin prescriptions. The
average cost of PEG2A prescriptions was $12,656, while ribavi-
rin prescriptions cost $9551, resulting in a total therapy cost of
$22,207. The average cost of PEG2B + R prescriptions was
slightly lower, at $21,681. The patients had fewer prescriptions
and lower costs for IFN + R therapy compared with the
PEG2A + R and PEG2B + R combination therapies. The patients
on monotherapies incurred the lowest prescription costs because
of lack of the ribavirin component. The patients received
PEG2A + R therapy for approximately 224 days (32 weeks). The
average overall duration for PEG2B + R was slightly lower at
214 days. The average duration of IFN + R was 187 days. The
patients on PEG2A and PEG2B monotherapies received treat-
ment for longer periods (233 and 283 days, respectively).
The mean MPR for the patients on PEG2A + R and
PEG2B + R was similar at 0.76 and 0.74, respectively. MPR was
the lowest for the patients on IFN + R (0.57). Approximately
60% of the patients on PEG2A + R and PEG2B + R were adher-
ent to therapy. Adherence rates were lower for PEG2A and
PEG2B monotherapies (46% and 47%, respectively) and for
IFN + R combination therapy (36%). Among the patients who
received treatment beyond 24 weeks, the average 48-week MPR
for PEG2A + R and PEG2B + R was slightly lower, at 0.73.
Treatment Patterns and Adherence by
Clinical Characteristics
Table 5 presents treatment patterns of the patients who initiated
combination peginterferon regimens (PEG2A + R or PEG2B + R)
Table 3 Treatment prevalence
Chronic HCV
(N = 5086)
N (%)
Treatment initiated*
Peginterferon alfa-2a + ribavirin 2422 (47.62)
Peginterferon alfa-2b + ribavirin 2230 (43.85)
Peginterferon alfa-2a monotherapy 158 (3.11)
Peginterferon alfa-2b monotherapy 152 (2.99)
Interferon alfa-2a + ribavirin 1 (0.02)
Interferon alfa-2b + ribavirin 15 (0.29)
Interferon alfa-2a monotherapy 1 (0.02)
Interferon alfa-2b monotherapy 8 (0.16)
Interferon alfacon-1 (consensus interferon) + ribavirin 85 (1.67)
Interferon alfacon-1 (consensus interferon) monotherapy 14 (0.28)
Months between HCV diagnosis and treatment initiation
(for patients initiating treatment before ﬁrst observed
diagnosis)
Mean; standard deviation 2.20; 2.29
Median 1
Range: minimum, maximum 0, 6
Months between HCV diagnosis and treatment initiation
(for patients initiating treatment after ﬁrst observed
diagnosis)
Mean; standard deviation 6.65; 6.94
Median 4
Range: minimum, maximum 1, 47
Categories
Up to 6 months before index diagnosis 738 (14.51)
1–6 months after index diagnosis 2897 (56.96)
7–12 months after index diagnosis 864 (16.99)
13–18 months after index diagnosis 289 (5.68)
19–24 months after index diagnosis 132 (2.60)
25–36 months after index diagnosis 128 (2.52)
Greater than 36 months after index diagnosis 38 (0.75)
*Includes prescription drugs initiated at any point 6 months before ﬁrst observed HCV
diagnosis or at any time after the ﬁrst observed HCV diagnosis.
HCV, hepatitis C virus.
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stratiﬁed by genotype, SVR attainment, and disease severity. As
anticipated, the patients infected with genotype 1 virus had
longer treatment duration (237 days) compared with 161 days
for the patients infected with genotype 2/3 virus. As a result,
those with genotype 1 had twice the number of prescriptions on
average and incurred higher prescription costs ($23,666 vs.
$14,979). MPR at week 24 was slightly higher for the patients
with genotype 1 compared with the patients with genotype 2/3.
The percentage of the patients who were adherent was the same
across both genotype categories.
When stratiﬁed by SVR attainment status, the number of
prescriptions, treatment costs, and duration of treatment were
slightly higher for those patients who attained SVR. The patients
who attained SVR had a signiﬁcantly higher MPR compared
with those patients who did not attain SVR (0.79 vs. 0.69).
Nearly 65% of the patients who attained SVR were adherent to
therapy compared with only 52% of those who did not attain
SVR. The patients who attained SVR were also more likely to
continue treatment beyond 24 weeks compared with those who
did not (72% vs. 59%). Among those patients who continued
beyond 24 weeks, however, the rate of adherence was similar
between the SVR attainers and the nonattainers.
The patients with severe disease had fewer prescriptions,
lower costs, and shorter treatment duration compared with the
mild and moderate patients. They also had much lower adher-
ence rates, perhaps because of a higher rate of treatment-related
adverse events. The average MPR for the patients with mild
disease was 0.82, for moderate disease, MPR was 0.76, and for
severe disease, MPR was 0.59. Adherence rates were 65%, 62%,
and 50%, respectively. Fewer patients with severe disease
received treatment beyond 24 weeks, compared with the patients
with mild and moderate disease.
Adherence and Costs
Table 6 presents generalized linear model estimates of the impact
of medication nonadherence on HCV-related and all-cause costs.
The adherent patients had greater total HCV-related costs com-
pared with the nonadherent patients ($20,132 vs. $12,259;
P < 0.01) primarily because of higher pharmacy costs incurred
from stricter reﬁll compliance by the adherent patients ($18,963
vs. $10,232; P < 0.01). When pharmacy costs are excluded, the
adherent patients incurred lower total HCV-related costs com-
pared with the nonadherent patients ($1370 vs. $2463; P < 0.01).
HCV-related inpatient costs incurred by the nonadherent patients
were signiﬁcantly greater than those costs incurred by the adher-
ent patients ($13,162 vs. $8733; P < 0.01). This could be due to
the fact that the nonadherent patients are more likely to experi-
ence disease progression, develop liver cirrhosis, and need expen-
sive inpatient procedures such as liver transplants. This
relationship could also be mediated by the observation of higher
adherence rates among those who attained SVR: in a subanalysis
conducted among the patients for whom SVR attainment was
evaluated, monthly per patient costs after treatment completion in
those who failed to attain SVR were roughly double ($1436) the
costs incurred by the patients who achieved SVR ($717). Finally,
the adherent patients incurred lower all-cause costs in all catego-
ries except physician ofﬁce visits and prescription drugs. Total
all-cause costs, excluding pharmacy, were $6320 for the nonad-
herent patients and $3693 for the adherent patients (P < 0.01).
Conclusions
Our study is subject to several limitations inherent in most analy-
ses of retrospective claims data. First, the patients were identiﬁed
based on ICD-9-CM diagnosis codes that if recorded inaccu-
rately, may have caused some of the patients to be misidentiﬁed
as having HCV. In addition, the patients who were coded as
having acute HCV, and therefore excluded from our analysis,
could in fact be chronic HCV patients who were misclassiﬁed.
The impact of misclassiﬁcation bias stemming from analyses of
ICD-9-CM codes in claims data has been described further in
previous research [18,19]. The validity of our results therefore
depends on the accuracy of record keeping among providers who
submit claims in the Ingenix Impact database. Second, laboratory
test results were available for only a small subset of the patient
population. Better availability of laboratory results would
provide genotype information for a larger number of patients,
thereby allowing us to assess adherence over the entire treatment
period of 48 weeks for the patients with genotype 1. Third,
medication reﬁll patterns in administrative data, although reﬂec-
tive of real-world prescription dispensing, may not reveal the true
intent or directions of the prescribing physician. Failure to reﬁll
a prescription may occur for clinically appropriate reasons, such
as treatment discontinuation because of medication side effects,
adverse drug interactions, medication titration, or abnormal
laboratory results [20]. These factors may cause MPR-based
compliance measures in claims data to understate actual adher-
ence. Conversely, the observation of a prescription claim assumes
complete use of the medication obtained. It is possible, however,
that individuals may dispose of medication before reﬁll or stock-
pile it for future use [20]. These factors may cause the MPR to
overstate actual adherence. In spite of these considerations,
administrative prescription data remain a valid and widely
accepted source for estimating adherence with chronic-use medi-
cations using validated measures such as the MPR [11,20].
Table 6 HCV-related and all-cause costs by 24-week adherence status
HCV-related costs in $ All-cause costs in $
Adherent (N = 2,970) Nonadherent (N = 2,116)
P Value
Adherent (N = 2,970) Nonadherent (N = 2,116)
P ValueMean (SD) Mean (SD) Mean (SD) Mean (SD)
Hospitalizations 8,733 (2,282) 13,612 (4,425) <0.0001 10,920 (2,651) 17,377 (5,591) <0.0001
ER visits 601 (177) 764 (213) <0.0001 691 (113) 881 (305) <0.0001
Ofﬁce visits 435 (37) 320 (40) <0.0001 1,115 (271) 1,082 (330) <0.0001
Other OP/ancillary 772 (258) 835 (195) <0.0001 1,705 (496) 2,508 (1,079) <0.0001
Laboratory services 491 (78) 425 (77) <0.0001 666 (118) 671 (207) 0.2979
Pharmacy 18,963 (439) 10,232 (265) <0.0001 21,953 (812) 12,645 (1,356) <0.0001
Nonpharmacy total 1,370 (420) 2,463 (1,371) <0.0001 3,693 (1,205) 6,320 (3,545) <0.0001
Total 20,132 (436) 12,259 (1,218) <0.0001 25,651 (1,864) 18,910 (4,492) <0.0001
Rows represent separate regression models and therefore do not add up to the total; all cost estimates adjusted for baseline patient characteristics via multivariate GLM regression; sample
sizes for skilled nursing facility admissions and home health visits were too small for a multivariate analysis; all costs evaluated over all patients over a 24-week period after treatment initiation.
ER, emergency room; GLM, generalized linear model; HCV, hepatitis C virus; OP, outpatient.
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Finally, our database captures only three ICD-9-CM codes (one
primary code and two secondary codes) for each claim. Although
we deﬁne HCV-related costs based on claims with an HCV
diagnosis in the primary or either of the nonprimary positions,
HCV diagnoses lower than the third position were not captured.
Because HCV may still yield a contribution to the reason for and
costs of a health-care encounter even at lower coding positions,
our estimates of direct HCV-related costs are likely conservative.
Despite these limitations, this is the ﬁrst study to document in
detail real-world treatment patterns and adherence rates for key
therapies for chronic HCV among a population of managed care
enrollees in the United States. Our study found that peginterferon
plus ribavirin combination regimens are the mainstay of HCV
treatment. Combination therapy patients with genotype 1
received treatment for only 33 weeks on average compared with
the expected treatment length of 48 weeks. Combination thera-
pies are also costly, with managed care payers incurring over
$20,000 per patient for treatment. Adherence to HCV treatments
appears to be suboptimal, and with the exception of pharmacy
costs, nonadherence has a signiﬁcant negative impact on disease-
speciﬁc and all-cause medical costs. Inpatient costs are the key
drivers of increased costs among nonadherent patients. New
therapies with greater efﬁcacy or those that promote better
adherence and impose a lower cost burden on patients and
payers might help in improving SVR.
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